Anett Rancz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anett Rancz has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
Péter Hegyi
4 shared publications- Péter Hegyi
Translational Pancreatology Research Group Interdisciplinary Center of Excellence for Research Development and Innovation University of Szeged Szeged Hungary
4 shared publications - Andrea Szentesi
Institute for Translational Medicine Medical School University of Pécs Pécs Hungary
2 shared publications - Boglárka Lilla Szentes
Centre for Translational Medicine, Semmelweis University, 1085 Budapest, Hungary
2 shared publications - Brigitta Teutsch
Centre for Translational Medicine, Semmelweis University, 1085 Budapest, Hungary
2 shared publications - Emese Mihály
Semmelweis Egyetem, Általános Orvostudományi Kar II. Belgyógyászati Klinika Budapest Szentkirályi u. 46. 1088
2 shared publications
Latest Publications
- Open Access
- 14 November 2026
- Published by Elsevier in JAAD International
Efficacy and Safety of Treatments for Keloids and Hypertrophic Scars: A Systematic Review and Network Meta-analysis
- 14 November 2026
- Published by Elsevier in JAAD International
Open AccessEfficacy and Safety of Treatments for Keloids and Hypertrophic Scars: A Systematic Review and Network Meta-analysis
- Open Access
- 8 September 2026
- Published by Wiley in Clinical and Translational Medicine
- Vol. 16 (9)
Evidence‐based ranking of diabetes prevention in prediabetes: A comprehensive network meta‐analysis of 378 randomised controlled trials
Background: Ten percent of the global population presents impaired glucose tolerance. Although numerous interventions have been investigated to prevent type 2 diabetes (T2D), their comparative effectiveness remains uncertain. In this study, we assessed and ranked current pharmacological and non‐pharmacological interventions for preventing diabetes in individuals with prediabetes. Methods: The study protocol was registered on PROSPERO (CRD42023473875). Randomised controlled trials (RCTs) reporting on adult patients with prediabetes undergoing any intervention addressing dysglycaemia were eligible. Our systematic search was conducted from database inception to 19 December 2025 in three databases (MEDLINE, Embase and Cochrane Library [CENTRAL]). Network meta‐analysis was performed using the random‐effect frequentist method. Our primary outcomes were the incidence of T2D, haemoglobin A1c (HbA1c), fasting plasma glucose (FPG) and 2‐h glucose after the glucose oral tolerance test (2hPG) expressed as relative risk (RR) and mean difference (MD), respectively, with the corresponding 95% confidence intervals (CIs). Results: We included 378 RCTs comprising 113 122 patients. The highest risk reduction for T2D when compared with control was obtained with dual incretin‐based therapy (glucagon‐like peptide 1 [GLP‐1] and gastric inhibitory polypeptide (GIP) receptor agonists [GLP‐1 + GIP RAs]) (RR = .1, CI [.05; .21]), with GLP‐1 receptor agonists (GLP‐1 RAs) ranking second (RR = .26, CI [.19; .4]) followed closely by metformin plus intensive lifestyle intervention (ILI) (RR = .27, CI [.12; .64]). Only curcumin (MD = −.49, CI [−.70; −.28]), dual GLP‐1 + GIP RA (MD = −.46, CI [−.63; −.29]), single GLP‐1 RA (MD = −.41, CI [−.50; −.31]) and physical activity (MD = −.35, CI [−.48; −.23]) achieved >.3% HbA1c reductions after 1 year. Sulphonylureas and physical activity were most effective for the 1‐year FPG decrease, while the greatest 2hPG reduction was obtained with zinc supplementation and sulphonylureas. Conclusion: Incretin‐based therapies, particularly dual GLP‐1 + GIP RA and single GLP‐1 RA, followed by metformin together with ILI, are the most effective interventions to prevent T2D in patients with prediabetes.
- 8 September 2026
- Published by Wiley in Clinical and Translational Medicine
- Vol. 16 (9)
Open AccessEvidence‐based ranking of diabetes prevention in prediabetes: A comprehensive network meta‐analysis of 378 randomised controlled trials
Background: Ten percent of the global population presents impaired glucose tolerance. Although numerous interventions have been investigated to prevent type 2 diabetes (T2D), their comparative effectiveness remains uncertain. In this study, we assessed and ranked current pharmacological and non‐pharmacological interventions for preventing diabetes in individuals with prediabetes. Methods: The study protocol was registered on PROSPERO (CRD42023473875). Randomised controlled trials (RCTs) reporting on adult patients with prediabetes undergoing any intervention addressing dysglycaemia were eligible. Our systematic search was conducted from database inception to 19 December 2025 in three databases (MEDLINE, Embase and Cochrane Library [CENTRAL]). Network meta‐analysis was performed using the random‐effect frequentist method. Our primary outcomes were the incidence of T2D, haemoglobin A1c (HbA1c), fasting plasma glucose (FPG) and 2‐h glucose after the glucose oral tolerance test (2hPG) expressed as relative risk (RR) and mean difference (MD), respectively, with the corresponding 95% confidence intervals (CIs). Results: We included 378 RCTs comprising 113 122 patients. The highest risk reduction for T2D when compared with control was obtained with dual incretin‐based therapy (glucagon‐like peptide 1 [GLP‐1] and gastric inhibitory polypeptide (GIP) receptor agonists [GLP‐1 + GIP RAs]) (RR = .1, CI [.05; .21]), with GLP‐1 receptor agonists (GLP‐1 RAs) ranking second (RR = .26, CI [.19; .4]) followed closely by metformin plus intensive lifestyle intervention (ILI) (RR = .27, CI [.12; .64]). Only curcumin (MD = −.49, CI [−.70; −.28]), dual GLP‐1 + GIP RA (MD = −.46, CI [−.63; −.29]), single GLP‐1 RA (MD = −.41, CI [−.50; −.31]) and physical activity (MD = −.35, CI [−.48; −.23]) achieved >.3% HbA1c reductions after 1 year. Sulphonylureas and physical activity were most effective for the 1‐year FPG decrease, while the greatest 2hPG reduction was obtained with zinc supplementation and sulphonylureas. Conclusion: Incretin‐based therapies, particularly dual GLP‐1 + GIP RA and single GLP‐1 RA, followed by metformin together with ILI, are the most effective interventions to prevent T2D in patients with prediabetes.
- Open Access
- 3 March 2026
- Published by Elsevier in Pancreatology
- Vol. 26 (3) , 404-411
Risk factors for pancreatic exocrine insufficiency after acute pancreatitis: A systematic review and meta-analysis
- 3 March 2026
- Published by Elsevier in Pancreatology
- Vol. 26 (3) , 404-411
Open AccessRisk factors for pancreatic exocrine insufficiency after acute pancreatitis: A systematic review and meta-analysis
- Open Access
- 7 February 2026
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 52 (4) , 111461
Neoadjuvant chemotherapy enables fertility preservation without compromising oncologic outcomes in early cervical cancer ≥2 cm: A systematic review and meta-analysis
- 7 February 2026
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 52 (4) , 111461
Open AccessNeoadjuvant chemotherapy enables fertility preservation without compromising oncologic outcomes in early cervical cancer ≥2 cm: A systematic review and meta-analysis
- Open Access
- 17 July 2025
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 40 (9) , 2148-2162
Risk Factors for Microscopic Colitis: A Systematic Review and Meta‐Analysis
Background: Microscopic colitis (MC) is still an underdiagnosed disease due to its primarily histological appearance. We aimed to address the scarcity and inconsistency of data on MC risk factors.Methods: Our protocol was prospectively registered in PROSPERO (CRD42022286624). We systematically searched PubMed, Embase, and Cochrane from inception to January 6, 2025. Cohort, case–control, and cross‐sectional studies were included. Controls were distinguished with or without a histopathological examination. We used the random‐effect model to calculate pooled odds ratios (ORs) with 95% confidence intervals (CIs).Results: The systematic search yielded 6493 articles, of which 45 were meta‐analyzed. We found increased odds for MC in the case of nonsteroidal anti‐inflammatory drug (NSAID) and statin use compared to histological (OR = 2.57, CI: 1.45–4.53; OR = 2.15, CI: 1.14–4.05) and random (OR = 2.56, CI: 1.13–5.79; OR = 1.84, CI: 0.58–5.80) controls. Our results did not show an association between proton pump inhibitors (PPIs) and MC, compared to histological controls (OR = 1.81, CI: 0.75–4.35), except in the case of random controls (OR = 4.31, CI: 1.66–11.20). Neither current (OR = 1.35, CI: 0.88–2.06) nor previous smoking (OR = 1.26, CI: 0.67–2.39) increased the odds of MC compared to histological controls. In contrast, the odds doubled for current smoking and slightly changed for past smoking when MC patients were compared to random controls (OR = 2.40, CI: 1.64–3.50; OR = 1.11, CI: 0.93–1.31).Conclusions: NSAID and statin treatment were associated with an increased risk for MC compared to histological controls. PPIs and smoking showed only an association with MC when random controls were used.
- 17 July 2025
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 40 (9) , 2148-2162
Open AccessRisk Factors for Microscopic Colitis: A Systematic Review and Meta‐Analysis
Background: Microscopic colitis (MC) is still an underdiagnosed disease due to its primarily histological appearance. We aimed to address the scarcity and inconsistency of data on MC risk factors.Methods: Our protocol was prospectively registered in PROSPERO (CRD42022286624). We systematically searched PubMed, Embase, and Cochrane from inception to January 6, 2025. Cohort, case–control, and cross‐sectional studies were included. Controls were distinguished with or without a histopathological examination. We used the random‐effect model to calculate pooled odds ratios (ORs) with 95% confidence intervals (CIs).Results: The systematic search yielded 6493 articles, of which 45 were meta‐analyzed. We found increased odds for MC in the case of nonsteroidal anti‐inflammatory drug (NSAID) and statin use compared to histological (OR = 2.57, CI: 1.45–4.53; OR = 2.15, CI: 1.14–4.05) and random (OR = 2.56, CI: 1.13–5.79; OR = 1.84, CI: 0.58–5.80) controls. Our results did not show an association between proton pump inhibitors (PPIs) and MC, compared to histological controls (OR = 1.81, CI: 0.75–4.35), except in the case of random controls (OR = 4.31, CI: 1.66–11.20). Neither current (OR = 1.35, CI: 0.88–2.06) nor previous smoking (OR = 1.26, CI: 0.67–2.39) increased the odds of MC compared to histological controls. In contrast, the odds doubled for current smoking and slightly changed for past smoking when MC patients were compared to random controls (OR = 2.40, CI: 1.64–3.50; OR = 1.11, CI: 0.93–1.31).Conclusions: NSAID and statin treatment were associated with an increased risk for MC compared to histological controls. PPIs and smoking showed only an association with MC when random controls were used.
- Open Access
- 10 August 2024
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 50 (10) , 108599
End-to-end anastomosis provides similar quality-of-life, compared with other reconstructive techniques six months following total mesorectal excision: Systematic review and meta-analysis
- 10 August 2024
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 50 (10) , 108599
Open AccessEnd-to-end anastomosis provides similar quality-of-life, compared with other reconstructive techniques six months following total mesorectal excision: Systematic review and meta-analysis
- Open Access
- 1 January 2023
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 16
Microscopic colitis is a risk factor for low bone density: a systematic review and meta-analysis
Background: Microscopic colitis (MC) is a chronic inflammatory disease of the large bowel characterized by watery diarrhea, substantially decreasing the patient’s quality of life. Scarce data suggest that MC is associated with low bone density (LBD). Objectives: We aimed to assess whether MC is a risk factor for LBD and the proportion of patients with MC having LBD. Design: A systematic review and meta-analysis of studies reporting bone density measurements in MC patients. Data Sources and Methods: We systematically searched five databases from inception to October 16, 2021 (Pubmed, Embase, Cochrane, Scopus, and Web of Science). We used the random-effect model to calculate pooled odds ratios (ORs) and pooled event rates with 95% confidence intervals (CIs). To ascertain the quality of evidence of our outcomes, we followed the recommendations of the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) Working Group. Results: The systematic search yielded a total of 3046 articles. Four articles were eligible for quantitative synthesis. All of them used age- and sex-matched controls to evaluate LBD occurrence among patients with MC. The odds of having LBD were twofold increased (OR = 2.13, CI: 1.42–3.20) in the presence of MC, the odds of osteopenia occurrence were 2.4 (OR = 2.45, CI: 1.11–5.41), and of osteoporosis 1.4 (OR = 1.42, CI: 0.65–3.12). The proportion of LBD was 0.68 (CI: 0.56–0.78), osteopenia was 0.51 (CI: 0.43–0.58), and osteoporosis was 0.11 (CI: 0.07–0.16) among the MC population. Our findings’ certainty of the evidence was very low following the GRADEPro guideline. Conclusion: Our data demonstrate that MC is associated with a twofold risk for LBD. Based on our findings, we suggest screening patients for bone mineral density upon diagnosis of MC. Further prospective studies with higher patient numbers and longer follow-up periods on this topic are needed. Registration: Our protocol was prospectively registered with PROSPERO (CRD42021283392).
- 1 January 2023
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 16
Open AccessMicroscopic colitis is a risk factor for low bone density: a systematic review and meta-analysis
Background: Microscopic colitis (MC) is a chronic inflammatory disease of the large bowel characterized by watery diarrhea, substantially decreasing the patient’s quality of life. Scarce data suggest that MC is associated with low bone density (LBD). Objectives: We aimed to assess whether MC is a risk factor for LBD and the proportion of patients with MC having LBD. Design: A systematic review and meta-analysis of studies reporting bone density measurements in MC patients. Data Sources and Methods: We systematically searched five databases from inception to October 16, 2021 (Pubmed, Embase, Cochrane, Scopus, and Web of Science). We used the random-effect model to calculate pooled odds ratios (ORs) and pooled event rates with 95% confidence intervals (CIs). To ascertain the quality of evidence of our outcomes, we followed the recommendations of the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) Working Group. Results: The systematic search yielded a total of 3046 articles. Four articles were eligible for quantitative synthesis. All of them used age- and sex-matched controls to evaluate LBD occurrence among patients with MC. The odds of having LBD were twofold increased (OR = 2.13, CI: 1.42–3.20) in the presence of MC, the odds of osteopenia occurrence were 2.4 (OR = 2.45, CI: 1.11–5.41), and of osteoporosis 1.4 (OR = 1.42, CI: 0.65–3.12). The proportion of LBD was 0.68 (CI: 0.56–0.78), osteopenia was 0.51 (CI: 0.43–0.58), and osteoporosis was 0.11 (CI: 0.07–0.16) among the MC population. Our findings’ certainty of the evidence was very low following the GRADEPro guideline. Conclusion: Our data demonstrate that MC is associated with a twofold risk for LBD. Based on our findings, we suggest screening patients for bone mineral density upon diagnosis of MC. Further prospective studies with higher patient numbers and longer follow-up periods on this topic are needed. Registration: Our protocol was prospectively registered with PROSPERO (CRD42021283392).